Halozyme Therapeutics — Nov 3, 2025 release

The Company’s earnings per share guidance does not consider the impact of potential future share repurchases. Table 1. 2025 Financial Guidance   Previous Guidance Range New Guidance Range Total Revenue $1,275 to $1,355 million $1,300 to $1,375 million Royalty Revenue $825 to $860 million $850 to $880 million Adjusted EBITDA $865 to $915 million $885 to $935 million Non-GAAP Diluted EPS $6.00 to $6.40 $6.10 to $6.50 1 EBITDA, Adjusted EBITDA and Non-GAAP Diluted EPS are Non-GAAP financial measures. See “Note Regarding Use of Non-GAAP Financial Measures” below for an explanation of these measures. Reconciliations between GAAP reported and Non-GAAP financial information for actual results are provided at the end of this earnings release. Webcast and Conference Call Halozyme will host its Quarterly Update Conference Call for the third quarter ended September 30, 2025 today, Monday, November 3, 2025, at 1:30 p.m. PT/4:30 p.m. ET. The conference call may be accessed live with pre-registration via link: https://registrations.events/direct/Q4I78137280 . The call will also be webcast live through the “Investors” section of Halozyme’s corporate website and a recording will be made available following the close of the call. To access the webcast and additional documents related to the call, please visit Halozyme.com. About Halozyme Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the inno